CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended 31st March 202226-05-2022
26-05-2022
CAPLIN POINT LABORATORIES LTD. - 524742 - Reply To Clarification Sought By Exchange For Spurt In Volume In Shares Of The Company
Reply to clarification sought by Exchange for spurt in volume in shares of the Company20-05-2022
CAPLIN POINT LABORATORIES LTD. - 524742 - Clarification sought from Caplin Point Laboratories Ltd
The Exchange has sought clarification from Caplin Point Laboratories Ltd on May 20, 2022, with reference to Movement in Volume.The reply is awaited.20-05-2022
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of the Earnings Call - Q4 - FY 2021 - 2219-05-2022
Buy Caplin Point Laboratories; target of Rs 895: ICICI Direct
ICICI Direct is bullish on Caplin Point Laboratories has recommended buy rating on the stock with a target price of Rs 895 in its research report dated May 13, 2022.14-05-2022
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Further to our letter dated May 12, 2022 on the outcome of the Board meeting, we enclose herewith the copy of newspaper advertisement with respect to financial results published today in the Financial Express (English Newspaper) and Maalai Malar (Tamil Newspaper). Kindly take the same on your records.13-05-2022
Earnings Call for Q4FY22 of Caplin Point Laboratories
Conference Call with Caplin Point Laboratories Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.12-05-2022
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Results - Analyst/Investor Meet - Earnings Call - Q4 - Audio Recording12-05-2022
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
We wish to inform that the Nomination and Remuneration Committee of the Board of Directors of the Company at their meeting held on May 12, 2022, has allotted 11,666 equity shares of face value Rs. 2/- each, to the employees of the Company and its subsidiaries, upon exercise of stock options under Employee Stock Options Scheme(s) of the Company12-05-2022
Q4FY22 Quarterly Result Announced for Caplin Point Laboratories Ltd.
Pharmaceutical firm Caplin Point Laboratories declares Q4FY22 result: Total Annual Revenue at Rs. 1,308 Cr, up 21% YoY. PAT for the year up at Rs. 308 Cr, up 23% YoY. Cash Reserves at Rs. 694 Cr Top line of 2016 becomes Bottom line of 2022 Revenue for the year grew by 21% YoY to Rs. 1,308 Cr US Operating revenue grows 44% YoY to Rs. 122 Cr Gross margin for the year ended Mar’22 expanded by 53 bps to 56.1% PAT for the year is at Rs. 308 Cr up 22.7% YoY Cash and Cash Surplus at Rs. 694 Cr as of March 2022 – an increase of Rs 223 Cr over March 2021 balance. This increase is after a capex spend of Rs. 91 Cr during the year Free cash flow stood at Rs. 246 Cr as of Mar 22 Receivable days stand at 92 days as of Mar 22 Inventories are at Rs. 227 Cr (including in-transit inventory) Result PDF12-05-2022